Summary:
A multicenter, randomized, double-blind, placebo-controlled, 8-week study to evaluate the safety and efficacy of an investigational medication in patients with stage 1 or 2 essential hypertension.
Qualified Participants Must:
• Have high blood pressure
Qualified Participants May Receive:
All study-related evaluations and study medication at no cost, plus compensation for their time.